January 30, 2013

FDA approves three treatments for diabetes

FDA approves three treatments for diabetes
FDA approves three treatments for diabetes

Takeda announced that the FDA has approved Nesina (alogliptin), Oseni (alogliptin and Pioglitazone), and Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. Federal approval was based on worldwide placebo- and active-controlled clinical trials of Nesina involving more than 13,000 patients.

Nesina is a dipeptidyl peptidase-4 inhibitor (DPP-4i) that slows the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). Oseni, which combines alogliptin with pioglitazone, is the first to include both a DPP-4i and a thiazolidinedione (TZD) in a single tablet. Kazano combines alogliptin with metformin HCl, a biguanide also indicated for the treatment of diabetes.

Similar Articles
Related Topics

More in Products

FDA alerts providers to lack of sterility in NuVision Pharmacy products

The Food and Drug Administration expanded an alert about NuVision Pharmacy of Dallas, TX, on Saturday. It said investigators found poor sterile production practices that raised concern about a lack of sterility assurance for the company's sterile drug products.

Healthland buys American HealthTech

Healthland, an electronic health records vendor primarily focused on the rural hospital market, has acquired American HealthTech.

HealthLease purchase completed

CFG Capital Markets, the investment banking platform of Capital Funding Group, announced it was an advisor on a $141.7 million portfolio.